Alkermes (ALKS) Q4 2025 earnings review
Buying Growth to Mask Legacy Stagnation
Alkermes successfully executed a major strategic pivot, but the core financials look messy in the transition. Q4 2025 saw Total Revenue fall 11% YoY and GAAP Net Income plunge 66%, driven by the expiration of INVEGA SUSTENNA royalties. While the schizophrenia/bipolar drug LYBALVI remains a bright spot (+22% growth), older legacy products VIVITROL and ARISTADA have stalled. To buy its way back into growth, Alkermes just closed a massive $2.3B acquisition of Avadel Pharmaceuticals. This adds the narcolepsy drug LUMRYZ and pushes 2026 revenue guidance up over 20%. However, the heavy debt and integration costs will reverse the company's profitability, plunging Alkermes into an expected $125M net loss next year.
🐂 Bull Case
The addition of LUMRYZ instantly gives Alkermes a high-growth asset in the sleep medicine market, bridging the revenue gap left by expiring royalties and setting up commercial infrastructure for its own pipeline.
The Phase 2 Vibrance-1 data established alixorexton as a potential best-in-class orexin 2 agonist. Initiating Phase 3 in Q1 2026 sets the stage for a massive commercial opportunity in narcolepsy.
🐻 Bear Case
VIVITROL sales dropped 7.5% YoY in Q4, and ARISTADA grew less than 1%. Without LYBALVI, the legacy proprietary business is shrinking.
GAAP Net Income is guided to completely reverse from a $242M profit in 2025 to a $125M loss in 2026 due to $150M in inventory step-up costs and $100M in new amortization from the Avadel acquisition.
⚖️ Verdict: ⚪
Neutral. The pipeline is highly attractive and the strategic vision makes sense, but investors will have to stomach a year of ugly GAAP financials, high debt loads, and a stagnating legacy portfolio before the true value of the sleep franchise materializes.
Key Themes
LUMRYZ Acquisition Reverses Revenue Decline
The $2.3B Avadel acquisition closed on February 12, 2026, instantly transforming the company's growth profile. Management guides LUMRYZ to contribute $315-$335M in net sales for the remainder of 2026. This effectively replaces the lost INVEGA SUSTENNA manufacturing and royalty revenues, propelling overall top-line growth to an expected ~21% in 2026 after a flat 2025.
LYBALVI Continues to Carry the Legacy Business
LYBALVI remains the sole organic growth engine, decelerating slightly but still posting a robust 22% YoY growth in Q4 ($94.1M). Management's decision to expand the psychiatry sales force earlier in 2025 appears to be paying off, supporting a 25% YoY increase in total prescriptions and driving FY26 guidance to ~$390M.
Alixorexton Validates the Orexin Platform
Alkermes' orexin 2 receptor agonist, alixorexton (ALKS 2680), is advancing rapidly. After earning FDA Breakthrough Therapy designation in Narcolepsy Type 1, the drug will enter Phase 3 trials in Q1 2026. Beyond primary wakefulness endpoints, Phase 2 showed robust effects on fatigue and cognition—a key differentiator management plans to leverage for a competitive label.
Acquisition Debt Crushes Near-Term Profitability
While management touts the strategic benefits of Avadel, the financial toll is severe. Alkermes drained its cash reserves ($775M) and took on $1.525B in term loans. Consequently, net interest expense will jump to ~$80M in 2026. Combined with $180M in inventory step-up costs and $1.5B in new intellectual property amortization, this reverses the company's GAAP profitability into a projected $125M net loss for 2026.
VIVITROL and ARISTADA Hit a Wall
The legacy proprietary base is showing signs of fatigue. VIVITROL sales reversed to a 7.5% YoY decline in Q4 ($124.1M), while ARISTADA was essentially flat (+0.6%). Looking at 2026 guidance, management expects VIVITROL to grow a meager 0.4% and ARISTADA to grow 1.3%. This stagnation limits organic cash generation just when the company needs to service its new debt load.
Orexin Class Safety Scrutiny
Despite management downplaying the issue as a 'Wall Street focus', visual adverse events remain a critical risk factor for the entire orexin agonist class. Alkermes reported one severe visual AE leading to patient termination in Phase 2. While broader structural ophthalmic issues were absent, maintaining a clean safety profile in larger Phase 3 trials is imperative to secure approval.
Insulated from Macro Supply Chain Shocks
Alkermes enjoys a distinct structural advantage regarding potential tariffs and geopolitical supply chain disruptions. All proprietary commercial products are manufactured at its Ohio facility, with less than 5% of its Cost of Goods Sold derived from imported active pharmaceutical ingredients (APIs).
Other KPIs
Decelerating. Down from $543.3M in 2024. This 27% decline highlights the margin impact of losing high-margin royalty streams, despite tight control over SG&A and R&D expenses. For 2026, Adjusted EBITDA is guided flat at ~$390M, showing LUMRYZ revenue will take time to translate to bottom-line cash generation after transaction adjustments.
Reversing heavily. Down 44% YoY from $122.3M in 24Q4. The August 2024 expiration of the U.S. INVEGA SUSTENNA royalty has fully materialized, removing a significant, high-margin cash flow stream from the business.
While the year-end balance looks exceptionally strong (up from $824M in 2024), this liquidity is essentially gone. In February 2026, Alkermes deployed $775M of this cash to fund the Avadel acquisition, radically transforming the company's balance sheet from a net-cash to a heavy net-debt position.
Guidance
Accelerating. The midpoint of $1.785B represents a 21% YoY increase from 2025's $1.47B. This growth is entirely inorganic, driven by the anticipated $315-$335M contribution from the newly acquired LUMRYZ.
Decelerating. While still growing, the implied YoY growth drops from 23.8% in 2025 to roughly 12.5% at the 2026 midpoint. This suggests the initial rapid launch phase is moderating into a steady, mature growth curve.
Stable to Decelerating. VIVITROL is guided at $470M (midpoint), implying a negligible 0.4% YoY growth. ARISTADA is guided at $375M (midpoint), implying just 1.3% growth. Both franchises have effectively flatlined.
Stable. The midpoint of $390M is nearly identical to the $394M delivered in 2025. This indicates that while the Avadel deal spikes top-line revenue, the integration costs, and structural shift mean Alkermes will essentially tread water on core cash earnings in 2026.
Key Questions
LUMRYZ Run-Rate and Integration
LUMRYZ guidance of $315-$335M implies strong commercial execution for a newly acquired asset. What are the specific assumptions around sales force integration, and what buffer exists for potential operational disruption during the transition?
Legacy Product Endgame
With VIVITROL and ARISTADA growth stalling out entirely in your 2026 guidance, what is the strategy to manage these mature assets as generic pressures loom on the horizon?
Alixorexton Safety Monitoring
As Brilliance (Phase 3) initiates, will the FDA require stringent, regular ophthalmic monitoring, and how might that impact the operational speed and cost of the trials compared to Phase 2?
Path Back to GAAP Profitability
With a projected $125M GAAP net loss in 2026 due to $150M in inventory step-up and massive amortization, what is the realistic timeline for the combined entity to return to positive GAAP net income and deleverage the balance sheet?